Lead product in U.S. targeting CD19 in NHL, including PD-L1 positive, patients
ICT is developing ICTCAR014, a first-in-class dominant negative PD-1 (dnPD-1) CAR-T cell therapy, for treatment of NHL. Research has shown that the inhibition of PD-1 may enhance CAR-T cell function. ICTCAR014 targets CD19 and expresses a dnPD-1 protein that blocks the immunosuppression by cancer cells which is mediated by the interaction of PD-1 and PD-L1/2.
- dnPD-1 armored CD19 CAR-T construct targeting patients with relapsed or refractory non-Hodgkin lymphoma (NHL), including patients who are PD-L1 positive
- To date, patients treated in China (n=13) in IRB-approved human trials have demonstrated 92.3% objective response rate (53.8% complete remission; 38.5% partial remission). We observed significant tumor shrinkage, significant CAR-T cell expansion and limited toxicity